These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30504932)

  • 1. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
    Hernández-Boluda JC; Pereira A; Pastor-Galán I; Alvarez-Larrán A; Savchuk A; Puerta JM; Sánchez-Pina JM; Collado R; Díaz-González A; Angona A; Sagüés M; García-Gutiérrez V; Boqué C; Osorio S; Vallansot R; Palomera L; Mendizábal A; Casado LF; Pérez-Encinas M; Pérez-López R; Ferrer-Marín F; Sánchez-Guijo F; García C; Heras NL; López-Lorenzo JL; Cervantes F; Steegmann JL;
    Blood Cancer J; 2018 Dec; 8(10):91. PubMed ID: 30504932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
    Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
    Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
    Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
    Clark RE; Polydoros F; Apperley JF; Milojkovic D; Pocock C; Smith G; Byrne JL; de Lavallade H; O'Brien SG; Coffey T; Foroni L; Copland M
    Lancet Haematol; 2017 Jul; 4(7):e310-e316. PubMed ID: 28566209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
    Dou X; Qin Y; Huang X; Jiang Q
    Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
    Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
    Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
    Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Kim DDH; Novitzky-Basso I; Kim TS; Atenafu EG; Forrest D; Savoie L; Bence-Bruckler I; Keating MM; Busque L; Delage R; Xenocostas A; Liew E; Paulson K; Stockley T; Laneuville P; Lipton JH; Kamel-Reid S; Leber B
    Br J Haematol; 2021 May; 193(4):779-791. PubMed ID: 33876423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
    Yu L; Qin YZ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
    Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
    Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
    Chamoun K; Kantarjian H; Atallah R; Gonzalez GN; Issa GC; Rios MB; Garcia-Manero G; Borthakur G; Ravandi F; Jain N; Daver N; Konopleva M; DiNardo CD; Kadia T; Pemmaraju N; Jabbour E; Cortes J
    J Hematol Oncol; 2019 Jan; 12(1):1. PubMed ID: 30606227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
    Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.